Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000950170-23-015919
Filing Date
2023-04-28
Accepted
2023-04-28 16:48:54
Documents
4
Period of Report
2023-06-14

Document Format Files

Seq Description Document Type Size
1 DEF 14A janx_def_14a_2023.htm DEF 14A 864826
2 GRAPHIC img58054456_0.jpg GRAPHIC 4603
3 GRAPHIC img58054456_1.jpg GRAPHIC 889074
4 GRAPHIC img58054456_2.jpg GRAPHIC 570148
  Complete submission text file 0000950170-23-015919.txt   2878216
Mailing Address 10955 VISTA SORRENTO PARKWAY SUITE 200 SAN DIEGO CA 92130
Business Address 10955 VISTA SORRENTO PARKWAY SUITE 200 SAN DIEGO CA 92130 (858) 751-4493
Janux Therapeutics, Inc. (Filer) CIK: 0001817713 (see all company filings)

EIN.: 822289112 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-40475 | Film No.: 23867577
SIC: 2834 Pharmaceutical Preparations